# Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

Source: https://onco.cc/trials/nct07145255/  
OnCo record `nct07145255` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ADC in prostate cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by MBrace Therapeutics, now recruiting.

## Summary

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors is a phase 1/2 interventional study registered as NCT07145255 by MBrace Therapeutics, with 150 participants planned, started 2025-09-03 and due to reach its primary completion in 2029-09-30. Interventions recorded: ADC.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07145255
- Phase: 1/2
- Setting: A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors
- Sponsor: MBrace Therapeutics
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07145255: https://clinicaltrials.gov/study/NCT07145255

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [MBrace Therapeutics](https://onco.cc/companies/mbrace-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07145255.json